Literature DB >> 33902615

Targeting lactate dehydrogenase a improves radiotherapy efficacy in non-small cell lung cancer: from bedside to bench.

Yang Yang1,2,3, Yu Chong4, Mengyuan Chen5,6, Wumin Dai6,7, Xia Zhou5,6, Yongling Ji5,6, Guoqin Qiu5,6, Xianghui Du8,9.   

Abstract

BACKGROUND: Lactate dehydrogenase A (LDHA) is overexpressed and associated with poor prognosis in many kinds of cancer. In the current study, we evaluated the prognostic value of LDHA expression in non-small cell lung cancer (NSCLC), and tested whether LDHA inhibition might improve radiotherapy efficacy in NSCLC.
METHODS: LDHA expression was investigated in NSCLC patients, using online database and further verified by immunohistochemistry. The prognostic value of LDHA was evaluated using Kaplan-Meier plotter database. In vitro, two NSCLC cell lines were pretreated with oxamate, an inhibitor of LDHA, and colony formation method was performed to determine cellular radiosensitivity. Comet assay was used to detect DNA damage after irradiation. Flow cytometry was applied to test cell cycle progression and apoptosis, and monodansylcadaverine (MDC) staining was used to examine cell autophagy.
RESULTS: Both mRNA and protein levels of LDHA expression were up-regulated in NSCLC tissues. High LDHA expression was a poor prognostic factor and associated with radioresistance in NSCLC patients. LDHA inhibition by oxamate remarkably increased radiosensitivity in both A549 and H1975 cancer cells, and enhanced ionizing radiation (IR)-induced apoptosis and autophagy, accompanied by cell cycle distribution alternations. Furthermore, LDHA inhibition induced reactive oxygen species (ROS) accumulation and cellular ATP depletion, which might increase DNA injury and hinder DNA repair activity.
CONCLUSIONS: Our study suggests that inhibition of LDHA may be a potential strategy to improve radiotherapy efficacy in NSCLC patients, which needs to be further tested by clinical trials.

Entities:  

Keywords:  Apoptosis; DNA repair; LDHA; NSCLC; ROS; Radiosensitivity

Year:  2021        PMID: 33902615     DOI: 10.1186/s12967-021-02825-2

Source DB:  PubMed          Journal:  J Transl Med        ISSN: 1479-5876            Impact factor:   5.531


  57 in total

Review 1.  Radiotherapy treatment for lung cancer: Current status and future directions.

Authors:  Shalini K Vinod; Eric Hau
Journal:  Respirology       Date:  2020-06-09       Impact factor: 6.424

2.  Prognostic Value of Lactate Dehydrogenase Expression in Different Cancers: A Meta-Analysis.

Authors:  Jiancheng Lv; Zijian Zhou; Jingzi Wang; Hao Yu; Hongcheng Lu; Baorui Yuan; Jie Han; Rui Zhou; Xiaolei Zhang; Xiao Yang; Haiwei Yang; Pengchao Li; Qiang Lu
Journal:  Am J Med Sci       Date:  2019-10-01       Impact factor: 2.378

3.  Hypoxia-inducible proteins HIF1α and lactate dehydrogenase LDH5, key markers of anaerobic metabolism, relate with stem cell markers and poor post-radiotherapy outcome in bladder cancer.

Authors:  Michael I Koukourakis; Christos Kakouratos; Dimitra Kalamida; Zoi Bampali; Sophia Mavropoulou; Efthimios Sivridis; Alexandra Giatromanolaki
Journal:  Int J Radiat Biol       Date:  2016-03-24       Impact factor: 2.694

4.  Cancer statistics, 2020.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2020-01-08       Impact factor: 508.702

Review 5.  The Emerging Hallmarks of Cancer Metabolism.

Authors:  Natalya N Pavlova; Craig B Thompson
Journal:  Cell Metab       Date:  2016-01-12       Impact factor: 27.287

6.  Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

Authors:  Scott J Antonia; Augusto Villegas; Davey Daniel; David Vicente; Shuji Murakami; Rina Hui; Takashi Yokoi; Alberto Chiappori; Ki H Lee; Maike de Wit; Byoung C Cho; Maryam Bourhaba; Xavier Quantin; Takaaki Tokito; Tarek Mekhail; David Planchard; Young-Chul Kim; Christos S Karapetis; Sandrine Hiret; Gyula Ostoros; Kaoru Kubota; Jhanelle E Gray; Luis Paz-Ares; Javier de Castro Carpeño; Catherine Wadsworth; Giovanni Melillo; Haiyi Jiang; Yifan Huang; Phillip A Dennis; Mustafa Özgüroğlu
Journal:  N Engl J Med       Date:  2017-09-08       Impact factor: 91.245

7.  Prognostic and predictive role of lactate dehydrogenase 5 expression in colorectal cancer patients treated with PTK787/ZK 222584 (vatalanib) antiangiogenic therapy.

Authors:  Michael I Koukourakis; Alexandra Giatromanolaki; Efthimios Sivridis; Kevin C Gatter; Tanja Trarbach; Gunnar Folprecht; Michael M Shi; David Lebwohl; Tarja Jalava; Dirk Laurent; Gerold Meinhardt; Adrian L Harris
Journal:  Clin Cancer Res       Date:  2011-06-01       Impact factor: 12.531

8.  Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia.

Authors:  M Maftouh; A Avan; R Sciarrillo; C Granchi; L G Leon; R Rani; N Funel; K Smid; R Honeywell; U Boggi; F Minutolo; G J Peters; E Giovannetti
Journal:  Br J Cancer       Date:  2013-10-31       Impact factor: 7.640

9.  Lactate dehydrogenase 5 isoenzyme overexpression defines resistance of prostate cancer to radiotherapy.

Authors:  M I Koukourakis; A Giatromanolaki; M Panteliadou; S E Pouliliou; P S Chondrou; S Mavropoulou; E Sivridis
Journal:  Br J Cancer       Date:  2014-04-08       Impact factor: 7.640

10.  Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis.

Authors:  M I Koukourakis; A Giatromanolaki; E Sivridis; G Bougioukas; V Didilis; K C Gatter; A L Harris
Journal:  Br J Cancer       Date:  2003-09-01       Impact factor: 7.640

View more
  5 in total

Review 1.  The role of metabolic ecosystem in cancer progression - metabolic plasticity and mTOR hyperactivity in tumor tissues.

Authors:  Anna Sebestyén; Titanilla Dankó; Dániel Sztankovics; Dorottya Moldvai; Regina Raffay; Catherine Cervi; Ildikó Krencz; Viktória Zsiros; András Jeney; Gábor Petővári
Journal:  Cancer Metastasis Rev       Date:  2022-01-14       Impact factor: 9.264

Review 2.  Exploring the Role of Metabolites in Cancer and the Associated Nerve Crosstalk.

Authors:  Inah Gu; Emory Gregory; Casey Atwood; Sun-Ok Lee; Young Hye Song
Journal:  Nutrients       Date:  2022-04-21       Impact factor: 6.706

3.  miR-148a promotes cell sensitivity through downregulating SOS2 in radiation-resistant non-small cell lung cancer cells.

Authors:  Yan Zhang; Xiaoqian Hu
Journal:  Oncol Lett       Date:  2022-02-24       Impact factor: 2.967

4.  Transcriptional, chromatin, and metabolic landscapes of LDHA inhibitor-resistant pancreatic ductal adenocarcinoma.

Authors:  Parmanand Malvi; Vipin Rawat; Romi Gupta; Narendra Wajapeyee
Journal:  Front Oncol       Date:  2022-08-02       Impact factor: 5.738

5.  Design and Synthesis of New Pyrimidine-Quinolone Hybrids as Novel hLDHA Inhibitors.

Authors:  Iván Díaz; Sofia Salido; Manuel Nogueras; Justo Cobo
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.